P3 Health Partners Projects Significant Turnaround to Profitability in 2026 with $10M Adjusted EBITDA Midpoint
Summary
P3 Health Partners reported continued losses for 2025 but provided strong 2026 guidance, projecting a significant turnaround to positive Adjusted EBITDA at the midpoint.
Key Events
-
Full Year 2025 Financial Results
Reported a net loss of $323.1 million and an Adjusted EBITDA loss of $161.3 million for the year ended December 31, 2025.
-
Q4 2025 Performance
Posted a net loss of $165.7 million and an Adjusted EBITDA loss of $76.1 million for the fourth quarter.
-
Strong 2026 Adjusted EBITDA Guidance
Projected Adjusted EBITDA for 2026 in the range of negative $20 million to positive $40 million, with a midpoint of $10 million, representing approximately $170 million in year-over-year improvement.
-
2026 Revenue and Membership Outlook
Guided for 2026 total revenues between $1.50 billion and $1.70 billion, and at-risk members between 107,000 and 117,000.
Analysis
P3 Health Partners Inc. reported substantial losses for the full year and fourth quarter of 2025, with a net loss of $323.1 million and an Adjusted EBITDA loss of $161.3 million for the year. However, the company's 2026 guidance signals a dramatic shift, projecting Adjusted EBITDA to range from negative $20 million to positive $40 million, with a midpoint of $10 million. This represents an approximate $170 million year-over-year improvement, indicating a potential move to profitability. For a company with a relatively small market capitalization, this projected turnaround from significant losses to positive Adjusted EBITDA is a critical development that could fundamentally alter the investment thesis.
At the time of this filing, PIII was trading at $2.79 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $20.1M. The 52-week trading range was $1.52 to $11.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.